Free Shipping on orders over 50$

British Pound Sterling - GBP Euro - EUR US Dollar - USD (EUR)

Welcom to Gentaur Biotech Products!

Interferon Gamma, Mab anti_Bovine; Clone 5D10, ELISA

Be the first to review this product

Availability: In stock

€438.66
OR

Quick Overview

[#YSRTMCA2689] Interferon Gamma, Mab anti_Bovine; Clone 5D10, ELISA

Details

YSRTMCA2689 | Interferon Gamma, Mab anti_Bovine; Clone 5D10, ELISA, 0.25 mg.
More informations about Interferon Gamma, Mab anti_Bovine; Clone 5D10, ELISA in Antibody-antibodies.com

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.

(1) Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro.[TOP]

Pubmed ID :23876077
Publication Date : //
Programmed death-1 (PD-1) is a known immunoinhibitory receptor that contributes to immune evasion of various tumor cells and pathogens causing chronic infection, such as bovine leukemia virus (BLV) infection. First, in this study, to establish a method for the expression and functional analysis of bovine PD-1, hybridomas producing monoclonal antibodies (mAb) specific for bovine PD-1 were established. Treatment with these anti-PD-1 mAb enhanced interferon-gamma (IFN-γ) production of bovine peripheral blood mononuclear cells (PBMC). Next, to examine whether PD-1 blockade by anti-PD-1 mAb could upregulate the immune reaction during chronic infection, the expression and functional analysis of PD-1 in PBMC isolated from BLV-infected cattle with or without lymphoma were performed using anti-PD-1 mAb. The frequencies of both PD-1+ CD4+ T cells in blood and lymph node and PD-1+ CD8+ T cells in lymph node were higher in BLV-infected cattle with lymphoma than those without lymphoma or control uninfected cattle. PD-1 blockade enhanced IFN-γ production and proliferation and reduced BLV-gp51 expression and B-cell activation in PBMC from BLV-infected cattle in response to BLV-gp51 peptide mixture. These data show that anti-bovine PD-1 mAb could provide a new therapy to control BLV infection via upregulation of immune response.

Authors : Ikebuchi Ryoyo, Konnai Satoru, Okagawa Tomohiro, Yokoyama Kazumasa, Nakajima Chie, Suzuki Yasuhiko, Murata Shiro, Ohashi Kazuhiko,